https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 Temporal trends in, and associations of, early-career general practitioner prescriptions of second-line Type 2 Diabetes medications, 2010-2018 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49974 Wed 28 Feb 2024 16:14:53 AEDT ]]> A prompt to the web: the media and health information seeking behaviour https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:21738 Wed 11 Apr 2018 16:30:17 AEST ]]> Development of multidrug resistant tuberculosis in Bangladesh: a case-control study on risk factors https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:16808 Wed 11 Apr 2018 10:57:45 AEST ]]> The Australian Multiple Sclerosis (MS) Immunotherapy Study: a prospective, multicentre study of drug utilisation using the MSBase platform https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:13692 Wed 11 Apr 2018 09:50:56 AEST ]]> Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:24542 2 cm and/or node positive. At 3.9 years median follow-up (interquartile range 3.1- 4.8), 2 patients assigned letrozole (1.1%) and 17 patients assigned observation (9.5%) had experienced an invasive breast cancer event (difference 8.4%, 95% confidence interval 3.8% to 13.0%, log-rank test P = 0.0004). Twenty-four patients (13.4%) in the observation and 14 (7.7%) in the letrozole arm experienced a DFS event (log-rank P = 0.067). Adverse events linked to oestrogen depletion, but not serious adverse events, were more common with letrozole. Conclusion: These results should be considered exploratory, but lend weight to emerging data supporting longer duration endocrine therapy for hormone receptor-positive breast cancer, and offer insight into reintroduction of AI therapy. Clinical Trials Number: Australian New Zealand Clinical Trials Registry (www.anzctr.org.au), ACTRN12607000137493]]> Wed 09 Feb 2022 15:57:05 AEDT ]]> Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49074 40 years), sex (male or female), and number of comorbidities (≤1 and ≥2). Randomisation was done using random sequence generation in block randomisation in a 1:1 ratio. Budesonide dry powder was delivered using a turbohaler at a dose of 400 μg per actuation. Participants were asked to take two inhalations twice a day until symptom resolution. The primary endpoint was COVID-19-related urgent care visit, including emergency department assessment or hospitalisation, analysed for both the per-protocol and intention-to-treat (ITT) populations. The secondary outcomes were self-reported clinical recovery (symptom resolution), viral symptoms measured using the Common Cold Questionnare (CCQ) and the InFLUenza Patient Reported Outcome Questionnaire (FLUPro), body temperature, blood oxygen saturations, and SARS-CoV-2 viral load. The trial was stopped early after independent statistical review concluded that study outcome would not change with further participant enrolment. This trial is registered with ClinicalTrials.gov, NCT04416399. Findings: From July 16 to Dec 9, 2020, 167 participants were recruited and assessed for eligibility. 21 did not meet eligibility criteria and were excluded. 146 participants were randomly assigned—73 to usual care and 73 to budesonide. For the per-protocol population (n=139), the primary outcome occurred in ten (14%) of 70 participants in the usual care group and one (1%) of 69 participants in the budesonide group (difference in proportions 0·131, 95% CI 0·043 to 0·218; p=0·004). For the ITT population, the primary outcome occurred in 11 (15%) participants in the usual care group and two (3%) participants in the budesonide group (difference in proportions 0·123, 95% CI 0·033 to 0·213; p=0·009). The number needed to treat with inhaled budesonide to reduce COVID-19 deterioration was eight. Clinical recovery was 1 day shorter in the budesonide group compared with the usual care group (median 7 days [95% CI 6 to 9] in the budesonide group vs 8 days [7 to 11] in the usual care group; log-rank test p=0·007). The mean proportion of days with a fever in the first 14 days was lower in the budesonide group (2%, SD 6) than the usual care group (8%, SD 18; Wilcoxon test p=0·051) and the proportion of participants with at least 1 day of fever was lower in the budesonide group when compared with the usual care group. As-needed antipyretic medication was required for fewer proportion of days in the budesonide group compared with the usual care group (27% [IQR 0–50] vs 50% [15–71]; p=0·025) Fewer participants randomly assigned to budesonide had persistent symptoms at days 14 and 28 compared with participants receiving usual care (difference in proportions 0·204, 95% CI 0·075 to 0·334; p=0·003). The mean total score change in the CCQ and FLUPro over 14 days was significantly better in the budesonide group compared with the usual care group (CCQ mean difference −0·12, 95% CI −0·21 to −0·02 [p=0·016]; FLUPro mean difference −0·10, 95% CI −0·21 to −0·00 [p=0·044]). Blood oxygen saturations and SARS-CoV-2 load, measured by cycle threshold, were not different between the groups. Budesonide was safe, with only five (7%) participants reporting self-limiting adverse events. Interpretation: Early administration of inhaled budesonide reduced the likelihood of needing urgent medical care and reduced time to recovery after early COVID-19. Funding: National Institute for Health Research Biomedical Research Centre and AstraZeneca.]]> Wed 03 May 2023 16:14:55 AEST ]]> Clinician factors associated with prescribing nicotine replacement therapy in pregnancy: a cross-sectional survey of Australian obstetricians and general practitioners https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:33554 Tue 04 Jun 2019 15:39:56 AEST ]]> Clinical pharmacology in research, teaching and health care https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:10546 Sat 24 Mar 2018 08:10:20 AEDT ]]> The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline' https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27289 Sat 24 Mar 2018 07:40:21 AEDT ]]> A potential role for N-acetylcysteine in the management of methamphetamine dependence (commentary) https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27031 Mon 23 Sep 2019 12:39:49 AEST ]]>